X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc

GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty Medicines. The pharmaceutical group maintained its 2026 guidance, expecting turnover growth..
Physitrack plc

Physitrack compares practice management systems for UK physiotherapists

Physitrack’s UK guide compares eight physiotherapy practice management systems, including their pricing, clinical records, booking, exercise prescription and billing capabilities...
GSK

GSK reports 62% response rate in ovarian cancer trial

GSK has reported a confirmed response rate of 62% for its investigational drug mocertatug rezetecan in patients with platinum-resistant ovarian cancer, with median progression-free survival of 11.1 months in the..
CIZ

Cizzle Biotechnology raises £500,000 to support US lung cancer test adoption

Cizzle Biotechnology has conditionally raised £500,000 from existing shareholder Frazer Lang to support the commercial adoption of its CIZ1B lung cancer blood test in the USA and progress UK partner..
CIZ

Cizzle Biotechnology to present CIZ1B lung cancer test advances at SYNLAB Symposium

Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on 5 November 2026, highlighting technical evaluation work with the Christie Pathology..
VRCI

Verici Dx secures Asahi Kasei Therapeutics order for phase 2 transplant trial

Verici Dx will provide blood-based biomarker testing, including its Pre-Transplant Risk Assessment assay, for a Phase 2 clinical trial evaluating pegrizeprument, an investigational immunosuppressive therapy designed to prevent acute rejection..
PTRK

Physitrack CEO Henrik Molin outlines EMR Launch, AI strategy and 2027 growth plans

Physitrack CEO Henrik Molin discusses 14% year-on-year revenue growth, early sign-ups for its new electronic medical record system, remote therapeutic monitoring and plans to expand its AI-powered healthcare technology offering..
BIOG

Revolution Medicines advances cancer drug pipeline as European launch plans take shape

Revolution Medicines advances its European launch plans for RASONQUE following a positive EMA recommendation, while expanding its Phase 3 clinical programme in lung cancer...
GSK

GSK wins FDA approval for hepatitis B treatment Hibsago

GSK has received FDA approval for Hibsago (bepirovirsen), a new chronic hepatitis B treatment that achieved a 19% functional cure rate in Phase III trials after six months of treatment...

Physitrack revenue growth accelerates to 14% in Q3 2026

Physitrack reported 14% year-on-year revenue growth to €3.6m in Q3 2026, its strongest quarterly growth of the year. The company recorded its eighth consecutive quarter of positive operating cash flow,..
Genflow Biosciences Plc

Pet food industry turns to healthy ageing as demand for longevity products grows

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the needs of ageing cats and dogs could help manufacturers develop products..

Physitrack EMR attracts 480 clinics ahead of November launch

Physitrack PLC reports that 480 clinics representing more than 4,800 clinicians have signed up for its AI-powered electronic medical record platform ahead of its wider launch on 2 November 2026...
CIZ

Cizzle Biotechnology gains recognition for lung cancer test

Cizzle Biotechnology has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Genesis Conference, recognising progress with its CIZ1B biomarker test for early-stage lung cancer...
NFX

Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation

Nuformix plc reports statistically significant reductions in TGF-β/SMAD signalling following inhaled administration of NXP002 in a preclinical study, supporting its development as a potential treatment for idiopathic pulmonary fibrosis (IPF)...
GSK

GSK reports positive global results for lung cancer drug candidate

GSK reports first global data for investigational antibody-drug conjugate risvutatug rezetecan, showing a confirmed objective response rate of 61% at the 8 mg/kg dose in patients with relapsed extensive-stage small..
Oxford Biomedica Plc

OXB appoints former Sartorius CEO Joachim Kreuzburg as Non-Executive Director

OXB has appointed Dr Joachim Kreuzburg as an Independent Non-Executive Director, effective 23 November 2026. The former Sartorius CEO brings more than 20 years of life sciences leadership experience, including..
GENF

Genflow Biosciences CEO Dr Eric Leire discusses SIRT6 gene therapy results in aged dogs

Genflow Biosciences CEO Dr Eric Leire discusses interim SLAB-VET trial results, the potential of SIRT6 gene therapy in ageing dogs, plasmid DNA delivery, veterinary licensing opportunities and progress across the..
CIZ

Cizzle Biotechnology revises US payments as lung cancer test rollout advances

Cizzle Biotechnology has agreed revised payment terms with Cizzle Bio Inc, deferring US$1.81 million in guaranteed advance payments to December 2027 while converting advance royalties into upfront or milestone payments...
Cizzle Biotechnology Holdings plc

Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

Cizzle Bio has outlined clinical applications and ordering procedures for its CIZ1B lung cancer blood test, which is available through licensed healthcare providers in two Texas metropolitan areas...
Physitrack plc

Irish employers urged to strengthen workplace mental health support

Irish employers are being urged to combine employee assistance programmes with earlier mental health risk assessments to address workplace pressures and support employee wellbeing...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GSK Plc

GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty Medicines. The pharmaceutical group maintained its 2026 guidance, expecting turnover growth of 3% to 5% and core operating profit growth of 7% to 9%...
Physitrack plc

Physitrack compares practice management systems for UK physiotherapists

Physitrack’s UK guide compares eight physiotherapy practice management systems, including their pricing, clinical records, booking, exercise prescription and billing capabilities...
GSK

GSK reports 62% response rate in ovarian cancer trial

GSK has reported a confirmed response rate of 62% for its investigational drug mocertatug rezetecan in patients with platinum-resistant ovarian cancer, with median progression-free survival of 11.1 months in the Phase I BEHOLD-1 trial...
CIZ

Cizzle Biotechnology raises £500,000 to support US lung cancer test adoption

Cizzle Biotechnology has conditionally raised £500,000 from existing shareholder Frazer Lang to support the commercial adoption of its CIZ1B lung cancer blood test in the USA and progress UK partner agreements, including with the NHS...
CIZ

Cizzle Biotechnology to present CIZ1B lung cancer test advances at SYNLAB Symposium

Cizzle Biotechnology will present improvements to its CIZ1B lung cancer biomarker test at the SYNLAB Innovation Academy Symposium on 5 November 2026, highlighting technical evaluation work with the Christie Pathology Partnership and peer-reviewed research demonstrating test accuracy and reproducibility...
VRCI

Verici Dx secures Asahi Kasei Therapeutics order for phase 2 transplant trial

Verici Dx will provide blood-based biomarker testing, including its Pre-Transplant Risk Assessment assay, for a Phase 2 clinical trial evaluating pegrizeprument, an investigational immunosuppressive therapy designed to prevent acute rejection in solid organ transplant recipients...
PTRK

Physitrack CEO Henrik Molin outlines EMR Launch, AI strategy and 2027 growth plans

Physitrack CEO Henrik Molin discusses 14% year-on-year revenue growth, early sign-ups for its new electronic medical record system, remote therapeutic monitoring and plans to expand its AI-powered healthcare technology offering in 2027...
BIOG

Revolution Medicines advances cancer drug pipeline as European launch plans take shape

Revolution Medicines advances its European launch plans for RASONQUE following a positive EMA recommendation, while expanding its Phase 3 clinical programme in lung cancer...
GSK

GSK wins FDA approval for hepatitis B treatment Hibsago

GSK has received FDA approval for Hibsago (bepirovirsen), a new chronic hepatitis B treatment that achieved a 19% functional cure rate in Phase III trials after six months of treatment...

Physitrack revenue growth accelerates to 14% in Q3 2026

Physitrack reported 14% year-on-year revenue growth to €3.6m in Q3 2026, its strongest quarterly growth of the year. The company recorded its eighth consecutive quarter of positive operating cash flow, while 480 clinics signed up for its new electronic medical record platform ahead of paid subscriptions launching in January 2027...
Genflow Biosciences Plc

Pet food industry turns to healthy ageing as demand for longevity products grows

Growing interest in pet longevity is creating opportunities for specialised nutrition, supplements and veterinary treatments. Improved research into the needs of ageing cats and dogs could help manufacturers develop products with clearer evidence of their health benefits...

Physitrack EMR attracts 480 clinics ahead of November launch

Physitrack PLC reports that 480 clinics representing more than 4,800 clinicians have signed up for its AI-powered electronic medical record platform ahead of its wider launch on 2 November 2026...
CIZ

Cizzle Biotechnology gains recognition for lung cancer test

Cizzle Biotechnology has been shortlisted for Best Non-Therapeutic R&D Company of the Year at the One Nucleus Genesis Conference, recognising progress with its CIZ1B biomarker test for early-stage lung cancer...
NFX

Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation

Nuformix plc reports statistically significant reductions in TGF-β/SMAD signalling following inhaled administration of NXP002 in a preclinical study, supporting its development as a potential treatment for idiopathic pulmonary fibrosis (IPF)...
GSK

GSK reports positive global results for lung cancer drug candidate

GSK reports first global data for investigational antibody-drug conjugate risvutatug rezetecan, showing a confirmed objective response rate of 61% at the 8 mg/kg dose in patients with relapsed extensive-stage small cell lung cancer...
Oxford Biomedica Plc

OXB appoints former Sartorius CEO Joachim Kreuzburg as Non-Executive Director

OXB has appointed Dr Joachim Kreuzburg as an Independent Non-Executive Director, effective 23 November 2026. The former Sartorius CEO brings more than 20 years of life sciences leadership experience, including a record of business transformation, acquisitions and international growth, as OXB advances its cell and gene therapy CDMO strategy across the UK, France and the US...
GENF

Genflow Biosciences CEO Dr Eric Leire discusses SIRT6 gene therapy results in aged dogs

Genflow Biosciences CEO Dr Eric Leire discusses interim SLAB-VET trial results, the potential of SIRT6 gene therapy in ageing dogs, plasmid DNA delivery, veterinary licensing opportunities and progress across the company's human gene therapy programmes...
CIZ

Cizzle Biotechnology revises US payments as lung cancer test rollout advances

Cizzle Biotechnology has agreed revised payment terms with Cizzle Bio Inc, deferring US$1.81 million in guaranteed advance payments to December 2027 while converting advance royalties into upfront or milestone payments...
Cizzle Biotechnology Holdings plc

Cizzle Bio outlines clinical use and ordering process for CIZ1B lung cancer blood test

Cizzle Bio has outlined clinical applications and ordering procedures for its CIZ1B lung cancer blood test, which is available through licensed healthcare providers in two Texas metropolitan areas...
Physitrack plc

Irish employers urged to strengthen workplace mental health support

Irish employers are being urged to combine employee assistance programmes with earlier mental health risk assessments to address workplace pressures and support employee wellbeing...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple